In 2014, Xie et al. also reported that in 99 patients with colorectal cancer, UGT1A1 promoter methylation could inhibit gene expression, thereby affecting the metabolic level of irinotecan (CPT-11) [50]. This evidence concerns the gene UGT1A1 and colorectal cancer.